Pentixapharm Submits IND to FDA for Phase 3 PANDA Study

Pentixapharm Holding AG has submitted an Investigational New Drug (IND) application to the FDA for its Phase 3 PANDA trial. This trial evaluates a CXCR4-targeted diagnostic for hypertension with underlying primary aldosteronism in the U.S. This marks a significant step towards improving cardiovascular diagnostics.

The PANDA study aims to use PET/CT imaging to guide treatment decisions through non-invasive subtype differentiation. The study's design aligns with FDA guidelines, which could lead to a smooth approval pathway. If successful, this innovation could address the current limitations of adrenal venous sampling (AVS), offering a scalable and non-invasive alternative.

Pentixapharm is enhancing its manufacturing capabilities to support trial execution. The company is also exploring strategic partnerships to aid its expansion in the U.S., recognizing the growing need for precise diagnostic tools in cardiovascular medicine.